Abstract

PLANNING AND EVALUATION MSKCC relies on both the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as the many internal planning processes to support the review and evaluation of the research programs and core facilities at the Center. During the current grant period, the Center has continued to expand its laboratory and patientoriented research programs to meet its planned strategic goals. In addition, a new PhD degree-granting school was established, after an extensive evaluation and review process. At its annual meetings, the BSC has reviewed a number of research areas including: Computational Biology, Proteomics, Experimental Therapeutics, Health Disparities and Inclusion of Underrepresented Minorities in Clinical Trials, Stem Cell Research, Aging and Cancer, and Molecular Imaging.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-44
Application #
8182193
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
44
Fiscal Year
2009
Total Cost
$52,553
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Wen, Hannah Y; Brogi, Edi (2018) Lobular Carcinoma In Situ. Surg Pathol Clin 11:123-145
Aghajanian, Carol; Bell-McGuinn, Katherine M; Burris 3rd, Howard A et al. (2018) A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs 36:1016-1025
Pun, Shawn C; Landau, Heather J; Riedel, Elyn R et al. (2018) Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. J Am Soc Echocardiogr 31:64-70
Ring, Brian Z; Murali, Rajmohan; Soslow, Robert A et al. (2018) Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiol Biomarkers Prev 27:680-688
Shukla, Sachet A; Bachireddy, Pavan; Schilling, Bastian et al. (2018) Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell 173:624-633.e8
Chaft, Jamie E; Dagogo-Jack, Ibiayi; Santini, Fernando C et al. (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67-71
Petrovic, Ivana D; Migliacci, Jocelyn; Ganly, Ian et al. (2018) Ameloblastomas of the mandible and maxilla. Ear Nose Throat J 97:E26-E32
Nashat, Melissa A; Ricart Arbona, Rodolfo J; Lepherd, Michelle L et al. (2018) Ivermectin-compounded Feed Compared with Topical Moxidectin-Imidacloprid for Eradication of Demodex musculi in Laboratory Mice. J Am Assoc Lab Anim Sci 57:483-497
Roxburgh, Campbell S; Fenig, Yaniv M; Cercek, Andrea et al. (2018) Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Ann Surg Oncol :
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378:1976-1986

Showing the most recent 10 out of 8799 publications